Prevalence of elevated liver transaminases and their relationship with alcohol use in people living with HIV on anti-retroviral therapy in Uganda.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 16 12 2020
accepted: 04 03 2021
entrez: 1 6 2021
pubmed: 2 6 2021
medline: 21 10 2021
Statut: epublish

Résumé

Isoniazid preventive therapy (IPT) reduces tuberculosis reactivation and mortality among persons living with HIV (PLWH), yet hepatotoxicity concerns exclude "regular and heavy alcohol drinkers" from IPT. We aimed to determine the prevalence of elevated liver transaminases among PLWH on antiretroviral therapy (ART) who engage in alcohol use. The Immune Suppression Syndrome Clinic of Mbarara, Uganda. We defined elevated liver transaminases as ≥1.25 times (X) the upper limit of normal (ULN) for alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST). We evaluated the associations of current alcohol use and other variables of interest (sex, body mass index, and ART regimen) with elevated transaminases at study screening, using multivariable logistic regression to obtain adjusted odds ratios (aOR) and 95% confidence intervals (CI). Among 1301 participants (53% female, median age 39 years, 67.4% current alcohol use), 18.8% (95% CI: 16.8-21.1) had elevated transaminases pre-IPT, with few (1.1%) severe (≥5X the ULN). The proportion with any elevation among those currently using alcohol and those abstaining was 22.3% and 11.6%, respectively (p<0.01). In multivariable analyses, those currently using alcohol had higher odds of elevated transaminases compared to those abstaining (aOR 1.65, 95% CI 1.15-2.37) as did males compared to females (aOR 2.68, 95% CI 1.90-3.78). Pre-IPT elevated transaminases among PLWH receiving ART were common, similar to prior estimates, but severe elevations were rare. Current drinking and male sex were independently associated with elevated transaminases. Further research is needed to determine the implications of such transaminase elevations and alcohol use on providing IPT.

Sections du résumé

BACKGROUND
Isoniazid preventive therapy (IPT) reduces tuberculosis reactivation and mortality among persons living with HIV (PLWH), yet hepatotoxicity concerns exclude "regular and heavy alcohol drinkers" from IPT. We aimed to determine the prevalence of elevated liver transaminases among PLWH on antiretroviral therapy (ART) who engage in alcohol use.
SETTING
The Immune Suppression Syndrome Clinic of Mbarara, Uganda.
METHODS
We defined elevated liver transaminases as ≥1.25 times (X) the upper limit of normal (ULN) for alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST). We evaluated the associations of current alcohol use and other variables of interest (sex, body mass index, and ART regimen) with elevated transaminases at study screening, using multivariable logistic regression to obtain adjusted odds ratios (aOR) and 95% confidence intervals (CI).
RESULTS
Among 1301 participants (53% female, median age 39 years, 67.4% current alcohol use), 18.8% (95% CI: 16.8-21.1) had elevated transaminases pre-IPT, with few (1.1%) severe (≥5X the ULN). The proportion with any elevation among those currently using alcohol and those abstaining was 22.3% and 11.6%, respectively (p<0.01). In multivariable analyses, those currently using alcohol had higher odds of elevated transaminases compared to those abstaining (aOR 1.65, 95% CI 1.15-2.37) as did males compared to females (aOR 2.68, 95% CI 1.90-3.78).
CONCLUSIONS
Pre-IPT elevated transaminases among PLWH receiving ART were common, similar to prior estimates, but severe elevations were rare. Current drinking and male sex were independently associated with elevated transaminases. Further research is needed to determine the implications of such transaminase elevations and alcohol use on providing IPT.

Identifiants

pubmed: 34061870
doi: 10.1371/journal.pone.0250368
pii: PONE-D-20-39571
pmc: PMC8168875
doi:

Substances chimiques

Anti-HIV Agents 0
Transaminases EC 2.6.1.-

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0250368

Subventions

Organisme : NIAAA NIH HHS
ID : U24 AA020779
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI119037
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA020776
Pays : United States
Organisme : NIAAA NIH HHS
ID : K24 AA022586
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI042853
Pays : United States

Déclaration de conflit d'intérêts

Dr. Debbie Cheng serves on Data Safety and Monitoring Boards for Janssen. Her work for Janssen is unrelated to the submitted work and Janssen had no role in any aspect of this work. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

AIDS Care. 2017 Nov;29(11):1442-1447
pubmed: 28278568
HIV Med. 2012 Oct;13(9):541-8
pubmed: 22416813
Am Fam Physician. 2017 Dec 1;96(11):709-715
pubmed: 29431403
J Acquir Immune Defic Syndr. 2018 Apr 15;77(5):492-501
pubmed: 29303844
Eur J Gastroenterol Hepatol. 2015 Jan;27(1):1-7
pubmed: 25380394
J Acquir Immune Defic Syndr. 2018 Apr 1;77(4):405-412
pubmed: 29239900
J Acquir Immune Defic Syndr. 2018 May 1;78(1):54-61
pubmed: 29406428
Eur Respir J. 2017 Jul 13;50(1):
pubmed: 28705945
AIDS. 2007 Jun 19;21(10):1301-8
pubmed: 17545706
AIDS Patient Care STDS. 2008 Oct;22(10):787-95
pubmed: 18778241
Open Forum Infect Dis. 2015 Jan 20;2(1):ofu120
pubmed: 26034751
Ann Hepatol. 2011 Oct-Dec;10(4):502-7
pubmed: 21911892
AIDS Res Treat. 2019 Jun 2;2019:6375714
pubmed: 31275646
Clin Gastroenterol Hepatol. 2010 Feb;8(2):183-91
pubmed: 19800985
Addiction. 2016 Feb;111(2):272-9
pubmed: 26381193
BMC Public Health. 2009 Dec 05;9:450
pubmed: 19961618
Int J Tuberc Lung Dis. 2015 Jan;19(1):111-9
pubmed: 25519800
Ethiop J Health Sci. 2013 Nov;23(3):217-26
pubmed: 24307821
J Stud Alcohol Drugs. 2013 Mar;74(2):266-70
pubmed: 23384374
Alcohol Clin Exp Res. 2016 Nov;40(11):2292-2295
pubmed: 27716960
J Tuberc Res. 2016 Mar;4(1):18-22
pubmed: 27054144

Auteurs

J Morgan Freiman (JM)

Department of Medicine and Section of Infectious Diseases, Boston Medical Center, Boston, MA, United States of America.

Robin Fatch (R)

Department of Medicine, University of California, San Francisco, CA, United States of America.

Debbie Cheng (D)

Department of Biostatistics, Boston University School of Public Health, Boston, MA, United States of America.

Nneka Emenyonu (N)

Department of Medicine, University of California, San Francisco, CA, United States of America.

Christine Ngabirano (C)

Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.

Carolina Geadas (C)

Department of Medicine and Section of Infectious Diseases, Boston Medical Center, Boston, MA, United States of America.

Julian Adong (J)

Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.

Winnie R Muyindike (WR)

Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
Mbarara Regional Referral Hospital, Mbarara, Uganda.

Benjamin P Linas (BP)

Department of Medicine and Section of Infectious Diseases, Boston Medical Center, Boston, MA, United States of America.

Karen R Jacobson (KR)

Department of Medicine and Section of Infectious Diseases, Boston Medical Center, Boston, MA, United States of America.

Judith A Hahn (JA)

Department of Medicine, University of California, San Francisco, CA, United States of America.
Department of Epidemiology, University of California, San Francisco, San Francisco, CA, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH